Clinical Trial Update: STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease [Phase 3]

View source ↗

Summary

Phase 3 STOP-PKD trial evaluating SGLT2 inhibitors to improve prognosis in autosomal dominant polycystic kidney disease. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: University of Cologne | Conditions: Polycystic Kidney, Autosomal Dominant | Phase 3 | Status: RECRUITING